Homologous mesenchymal stem cells promote the emergence and growth of pulmonary metastases of the rat osteosarcoma cell line UMR‑106

Zhang,Peng; Dong,Ling; Long,Hua; Yang,Tong‑Tao; Zhou,Yong; Fan,Qing‑Yu; Ma,Bao‑An

doi:10.3892/ol.2014.2127

Homologous mesenchymal stem cells promote the emergence and growth of pulmonary metastases of the rat osteosarcoma cell line UMR‑106

Authors:
- Peng Zhang
- Ling Dong
- Hua Long
- Tong‑Tao Yang
- Yong Zhou
- Qing‑Yu Fan
- Bao‑An Ma
View Affiliations

Affiliations: Department of Orthopedic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China, Department of Physiology, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China
Published online on: May 8, 2014 https://doi.org/10.3892/ol.2014.2127
Pages: 127-132

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma (OS) is the most frequent primary bone sarcoma and tends to develop pulmonary metastasis. Studies have shown that mesenchymal stem cells (MSCs) are involved in OS growth and metastasis, but the mechanism remains unclear. The aim of the present study was to identify whether homologous MSCs could promote the growth and metastasis of OS in rats with a normal immune system. The OS cell line, UMR‑106, which originally derives from a Sprague‑Dawley (SD) rat‑transplantable osteogenic sarcoma with an osteoblastic phenotype, has a strong carcinogenic capability and a high lung metastasis. Xenotransplanted models of UMR‑106 with or without MSCs injected through the tibia (IT) or caudal vein (IV) were established. SD rats were randomly divided into six groups: Control, UMR‑106 (IT), MSCs (IV), UMR‑106 (IT) + MSCs (IV), UMR‑106 (IV) and UMR‑106 (IV) + MSCs (IV). Following injection, all rats were sacrificed at week 5, and the volume and quantity of metastatic sarcoma and the serum alkaline phosphatase levels were measured. There was no metastatic sarcoma in the liver, spleen and kidney in all groups. The rats in the MSCs (IV) + UMR‑106 (IV) group showed a significantly higher volume and number of pulmonary metastatic tumors than those of the UMR‑106 (IV) group. In pulmonary metastatic tissues, MSCs were found in the MSCs (IV) + UMR‑106 (IV) group, but not in the UMR‑106 (IT) + MSCs (IV) group. Notably, the expression of vascular endothelial growth factor (VEGF) was increased in the MSCs + UMR‑106 cells co‑culture system. The present study indicated that MSCs can significantly promote the pulmonary metastasis of the rat OS cell line, UMR‑106, with a normal immune system, and VEGF was involved in MSC‑promoted UMR‑106 emergence and growth of pulmonary metastasis.

View Figures

View References

1	Sleeman J and Steeg PS: Cancer metastasis as a therapeutic target. Eur J Cancer. 46:1177–1180. 2010.
2	Meyers PA and Gorlick R: Osteosarcoma. Pediatr Clin North Am. 44:973–989. 1997.
3	Aung L, Gorlick R, Healey JH, et al: Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcoma. J Clin Oncol. 21:342–348. 2003.
4	Chen X, Yang TT, Wang W, et al: Establishment and characterization of human osteosarcoma cell lines with different pulmonary metastatic potentials. Cytotechnology. 61:37–44. 2009.
5	Karnoub AE, Dash AB, Vo AP, et al: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 449:557–563. 2007.
6	Aboody KS, Brown A, Rainov NG, et al: Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA. 97:12846–12851. 2000.
7	De Palma M, Venneri MA, Roca C and Naldini L: Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med. 9:789–795. 2003.
8	Klopp AH, Gupta A, Spaeth E, Andreeff M and Marini FR III: Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells. 29:11–19. 2011.
9	Tsukamoto S, Honoki K, Fujii H, et al: Mesenchymal stem cells promote tumor engraftment and metastatic colonization in rat osteosarcoma model. Int J Oncol. 40:163–169. 2012.
10	Schall TJ, Jongstra J, Dyer BJ, et al: A human T cell-specific molecule is a member of a new gene family. J Immunol. 141:1018–1025. 1988.
11	Forrest SM, Ng KW, Findlay DM, et al: Characterization of an osteoblast-like clonal cell line which responds to both parathyroid hormone and calcitonin. Calcif Tissue Int. 37:51–56. 1985.
12	Yu Z, Sun H, Fan Q, Long H, Yang T and Ma B: Establishment of reproducible osteosarcoma rat model using orthotopic implantation technique. Oncol Rep. 21:1175–1180. 2009.
13	Tu XH, Song JX, Xue XJ, et al: Role of bone marrow-derived mesenchymal stem cells in a rat model of severe acute pancreatitis. World J Gastroenterol. 18:2270–2279. 2012.
14	Wang H and Chen L: Tumor microenviroment and hepatocellular carcinoma metastasis. J Gastroenterol Hepatol. 28(Suppl 1): S43–S48. 2013.
15	Xu WT, Bian ZY, Fan QM, Li G and Tang TT: Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. Cancer Lett. 281:32–41. 2009.
16	Hiratsuka S, Nakamura K, Iwai S, et al: MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell. 2:289–300. 2002.
17	Hiratsuka S, Watanabe A, Aburatani H and Maru Y: Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol. 8:1369–1375. 2006.
18	Kaplan RN, Riba RD, Zacharoulis S, et al: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 438:820–827. 2005.
19	Chambers AF, Groom AC and MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2:563–572. 2002.
20	Fidler IJ and Nicolson GL: Fate of recirculating B16 melanoma metastatic variant cells in parabiotic syngeneic recipients. J Natl Cancer Inst. 58:1867–1872. 1977.
21	Kaplan RN, Psaila B and Lyden D: Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond. Cancer Metastasis Rev. 25:521–529. 2006.
22	Zumsteg A and Christofori G: Corrupt policemen: inflammatory cells promote tumor angiogenesis. Curr Opin Oncol. 21:60–70. 2009.
23	Worth LL, Lafleur EA, Jia SF and Kleinerman ES: Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep. 9:823–827. 2002.
24	Plate K: From angiogenesis to lymphangiogenesis. Nat Med. 7:151–152. 2001.
25	Oda Y, Yamamoto H, Tamiya S, Matsuda S, Tanaka K, Yokoyama R, Iwamoto Y and Tsuneyoshi M: CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol. 19:738–745. 2006.
26	Zhang P, Dong L, Yan K, et al: CXCR4-mediated osteosarcoma growth and pulmonary metastasis is promoted by mesenchymal stem cells through VEGF. Oncol Rep. 30:1753–1761. 2013.
27	Furudoi A, Tanaka S, Haruma K, et al: Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. Oncology. 62:157–166. 2002.
28	Kitadai Y, Amioka T, Haruma K, et al: Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer. 93:662–666. 2001.
29	Tian X, Song S, Wu J, Meng L, Dong Z and Shou C: Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. Biochem Biophys Res Commun. 286:505–512. 2001.
30	McAllister SS, Gifford AM, Greiner AL, et al: Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell. 133:994–1005. 2008.
31	Shojaei F, Wu X, Qu X, et al: G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA. 106:6742–6747. 2009.
32	PosthumaDeBoer J, Witlox MA, Kaspers GJ and van Royen BJ: Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis. 28:493–503. 2011.